Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Vifor Pharma    VIFN   CH0364749348


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations


11/16/2020 | 09:35am EST

St Gallen - Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress.

Simultaneously, results were published in the peer-reviewed medical journal The Lancet. The study evaluated the effect of Ferinject (intravenous ferric carboxymaltose) on heart failure (HF) hospitalizations and cardiovascular (CV) mortality in iron deficient patients after hospital stabilization for acute heart failure (AHF).

The study demonstrated there were significantly fewer hospital readmissions due to HF among patients treated with Ferinject compared to placebo. After 52 weeks, patients who received iron supplementation were 26% less likely to be re-admitted to the hospital for HF compared to placebo, after only one or two injections [RR 0.74; 95% CI 0.58-0.94; p=0.013].

'This is the first study demonstrating the benefits of iron supplementation initiated in stabilized patients hospitalized for AHF,' said Prof Piotr Ponikowski, Principle Investigator and Head of the Department of Heart Diseases, Wroclaw Medical University in Wroclaw, Poland. 'The study showed that administration of Ferinject in stabilized AHF patients with iron deficiency significantly reduces the risk of subsequent HF hospitalizations, and highlights the need for AHF patients to be more frequently screened for iron deficiency.'

'We are delighted to have presented full data from the AFFIRM-AHF study at the American Heart Association Scientific Sessions congress. This important data strengthens the evidence previously generated in large studies such as FAIR-HF and CONFIRM-HF,' said Dr Klaus Henning Jensen, Chief Medical Officer Vifor Pharma. 'Iron deficiency is a frequent, yet often unrecognized co-morbidity in heart failure, and this trial makes a significant contribution to the growing body of evidence showing the importance of detecting and managing iron deficiency in patients after heart failure.'

On September 24, 2020Vifor Pharma announced that overall AFFIRM-AHF narrowly missed the conventional 5% statistical significance on the primary composite endpoint, but numerically reduced total CV death and HF re-hospitalization events by 21% [RR 0.79; 95% CI 0.62-1.01; p=0.059]. Ferinject was well tolerated and without unexpected safety findings. No increase in mortality was seen and death from cardiovascular (CV) causes was similar between groups [RR 0.96; 95% CI 0.70-1.32].

The outbreak of the COVID-19 pandemic resulted in significant disruption to the healthcare systems, with a 40% reduction in HF hospitalizations in Europe between March and June 20202. HF patients are particularly at risk when suffering COVID-19. Therefore prior to study completion, COVID-19 sensitivity analysis was pre-specified which excluded subjects reporting from the date of the outbreak in each country. Adjusted for COVID-19 impact the composite endpoint was more robust and significant [RR 0.75; 95% CI 0.59-0.96; p=0.024].

Additional significant results were seen with several secondary outcomes, including treatment benefits with Ferinject observed seen on the time to first HF hospitalization or CV death (p=0.030) and days lost due to HF hospitalizations and CV death (p=0.035). These effects were more pronounced in the pre-COVID-19 analyses.

AFFIRM-AHF is the first of three ongoing mortality and morbidity trials including FAIR-HF2 and HEART-FID to understand the full potential of Ferinject for those suffering from heart failure and iron deficiency. The study was a randomized, double-blind placebo-controlled trial with 1,108 patients in 15 countries, designed to evaluate the effect of Ferinject or placebo administered prior to and subsequent to discharge in patients after AHF and iron deficiency on recurrent HF hospitalizations and CV death at 52 weeks after randomization.

Iron deficiency is present in approximately 80% of patients after AHF and indicates poor prognosis. It is associated with poor quality of life and increased risk for hospitalization and mortality, regardless of the presence or absence of anemia. Hospitalization due to AHF represents a growing health care problem that is associated with a higher risk of adverse clinical outcomes and huge economic burden.


Nathalie Ponnier

Tel: +41 79 957 96 73

Email: media@viforpharma.com


The AFFIRM-AHF study is a multi-centre, randomised, double-blind, placebo-controlled trial, comparing the effect of Intravenous Ferric Carboxymaltose (FCM) on hospitalizations and mortality in iron deficient patients admitted for Acute Heart Failure (AHF). AFFIRM-AHF is the first study that evaluates the benefit of Ferinject on hospitalizations and mortality in a very high risk population with iron deficiency and admitted in hospital for an episode of acute heart failure.

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about VIFOR PHARMA
2020ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacop..
2020VIFOR PHARMA : VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Tri..
2020Octavian Lowers Price Target on Vifor Pharma, Maintains Buy Recommendation
2020Swiss drugmaker Vifor had bid interest but talks halted - sources
2020MARKET CHATTER : Vifor Pharma Rejects $11 Billion Offer, Other Bids; Stock Up 7%
2020VIFOR PHARMA : supports Iron Deficiency Day 2020 to highlight global impact on h..
2020Research Partners Maintains Price Target on Vifor Pharma, Initiates Coverage ..
2020VIFOR PHARMA : VFMCRP and Fresenius Kabi expand collaboration in nephrology in C..
2020VIFOR PHARMA : Full results from affirm-ahf study show ferinject significantly r..
2020Vifor Pharma Study for Ferinject Shows Reduction in Hospitalizations of Heart..
More news
Sales 2020 1 845 M 2 077 M 2 077 M
Net income 2020 321 M 361 M 361 M
Net cash 2020 481 M 541 M 541 M
P/E ratio 2020 26,5x
Yield 2020 1,50%
Capitalization 8 933 M 10 049 M 10 060 M
EV / Sales 2020 4,58x
EV / Sales 2021 4,19x
Nbr of Employees 2 733
Free-Float 71,8%
Duration : Period :
Vifor Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIFOR PHARMA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 140,44 CHF
Last Close Price 137,65 CHF
Spread / Highest target 32,2%
Spread / Average Target 2,03%
Spread / Lowest Target -12,8%
EPS Revisions
Managers and Directors
Stefan Schulze President, Chief Executive & Operating Officer
Jacques Theurillat Chairman
Colin Bond Chief Financial Officer
Klaus Henning Jensen Chief Medical Officer
Etienne Jornod Honorary Chairman
Sector and Competitors
1st jan.Capitalization (M$)
VIFOR PHARMA-1.51%9 976
JOHNSON & JOHNSON3.43%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.22%203 993